Sonoma Pharmaceuticals, Inc. (SNOA): Nasdaq/NYSE listing notice — Nasdaq grants Sonoma Pharmaceuticals 180-day extension to meet $1.00 bid price rule

Sonoma Pharmaceuticals, Inc.

Company received until September 16, 2024 to regain compliance with Nasdaq minimum $1.00 closing bid price rule.
Initial compliance deadline of March 20, 2024 was not met; deficiency first disclosed in September 2023.
If bid price closes at $1.00+ for 10 consecutive business days before Sept 16, Nasdaq will confirm compliance.
Failure to cure by Sept 16 could lead to delisting; company may appeal or consider reverse stock split.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Sonoma Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock. As previously disclosed in the

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.